
    
      The study is divided into two parts, Dose Escalation (Part 1) in participants with NSCLC and
      TNBC without acceptable alternative treatment options, followed by Dose Expansion (Part 2) in
      participants with NSCLC who have progressed on or after treatment with platinum-based
      chemotherapy and treatment with 1 immune checkpoint inhibitor, given concurrently or
      sequentially with chemotherapy.

      Part 1 has been completed.
    
  